Hyderabad-based Suven Life Sciences is presenting pre-clinical data of investigational new chemical entities (NCEs) from its own portfolio at the Neuroscience 2007 meeting, being held at San Diego, from November 3 to 7.Neuroscience is the annual meeting of the Society of Neuroscience (SFN) and more than 30,000 neuro scientists from across the world covering all the major pharma and academic research institutions are attending the meet.Suven is presenting new data of its NCEs in the five promising areas of neuroscience - Alzheimer's, schizophrenia, Parkinson, sleep and obesity diseases - for which the company was granted nine product patents (two from the European Union, three from India, two each from Australia and the New Zealand)."These areas present significant unmet medical need for which current treatment options are insufficient. Suven has a number of programmes in each of these areas, focusing on novel approaches that may lead to the development of new therapies for patients. All these programmes belong to Suven's in-house drug discovery programme and does not involve any partner of collaborator," the company stated in a press release.
